BACKGROUND: Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome. METHODS: Thirty-nine patients were identified between 1972 and 2006. RESULTS: At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence. CONCLUSIONS: Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential. (c) 2008 Wiley Periodicals, Inc.
BACKGROUND: Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome. METHODS: Thirty-nine patients were identified between 1972 and 2006. RESULTS: At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence. CONCLUSIONS: Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential. (c) 2008 Wiley Periodicals, Inc.
Authors: Justin G Peacock; William S Harmsen; Michael J Link; Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Yolanda I Garces; Michelle A Neben Wittich; Daniel J Ma; Sean S Park; Robert L Foote Journal: J Neurol Surg B Skull Base Date: 2016-07-06
Authors: Diana Bell; Rami Saade; Dianna Roberts; Thomas J Ow; Michael Kupferman; Franco DeMonte; Ehab Y Hanna Journal: Head Neck Pathol Date: 2014-05-08
Authors: Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten Journal: J Neurooncol Date: 2009-09-20 Impact factor: 4.130
Authors: Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy Journal: J Neurol Surg B Skull Base Date: 2017-11-01
Authors: Gurvinder Kaur; Ari J Kane; Michael E Sughrue; Michelle Madden; Michael C Oh; Matthew Z Sun; Michael Safaee; Ivan El-Sayed; Manish Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa Journal: J Clin Neurosci Date: 2012-12-21 Impact factor: 1.961